PH12019501087A1 - A pharmaceutical composition for averting opioid addiction - Google Patents

A pharmaceutical composition for averting opioid addiction

Info

Publication number
PH12019501087A1
PH12019501087A1 PH12019501087A PH12019501087A PH12019501087A1 PH 12019501087 A1 PH12019501087 A1 PH 12019501087A1 PH 12019501087 A PH12019501087 A PH 12019501087A PH 12019501087 A PH12019501087 A PH 12019501087A PH 12019501087 A1 PH12019501087 A1 PH 12019501087A1
Authority
PH
Philippines
Prior art keywords
averting
patient
pharmaceutical composition
opioid addiction
opioid
Prior art date
Application number
PH12019501087A
Other languages
English (en)
Inventor
Catherine Stehman-Breen
John Davis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PH12019501087A1 publication Critical patent/PH12019501087A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PH12019501087A 2016-11-29 2019-05-16 A pharmaceutical composition for averting opioid addiction PH12019501087A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (1)

Publication Number Publication Date
PH12019501087A1 true PH12019501087A1 (en) 2019-08-19

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019501087A PH12019501087A1 (en) 2016-11-29 2019-05-16 A pharmaceutical composition for averting opioid addiction

Country Status (18)

Country Link
US (2) US10736961B2 (enExample)
EP (1) EP3548082B1 (enExample)
JP (1) JP7071975B2 (enExample)
KR (1) KR20190090820A (enExample)
CN (1) CN110072549A (enExample)
AU (1) AU2017366870B2 (enExample)
BR (1) BR112019010331A2 (enExample)
CA (1) CA3045116A1 (enExample)
CL (1) CL2019001385A1 (enExample)
CO (1) CO2019005247A2 (enExample)
EA (1) EA201991283A9 (enExample)
IL (1) IL266640B (enExample)
MA (2) MA46951A (enExample)
MX (1) MX2019006013A (enExample)
MY (1) MY200701A (enExample)
PH (1) PH12019501087A1 (enExample)
WO (1) WO2018102294A1 (enExample)
ZA (1) ZA201902967B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7460598B2 (ja) * 2018-08-10 2024-04-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 膝および／または股関節痛の安全で効果的な処置用の医薬組成物
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7988967B2 (en) * 2007-08-10 2011-08-02 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
JP5918246B2 (ja) 2010-10-06 2016-05-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤

Also Published As

Publication number Publication date
JP7071975B2 (ja) 2022-05-19
MA45890B2 (fr) 2022-10-31
BR112019010331A2 (pt) 2019-10-22
AU2017366870A1 (en) 2019-06-06
CA3045116A1 (en) 2018-06-07
EA201991283A1 (ru) 2019-09-30
CL2019001385A1 (es) 2019-07-26
US11491222B2 (en) 2022-11-08
ZA201902967B (en) 2024-10-30
MA45890A1 (fr) 2020-02-28
IL266640B (en) 2022-09-01
US20180147280A1 (en) 2018-05-31
CN110072549A (zh) 2019-07-30
KR20190090820A (ko) 2019-08-02
US10736961B2 (en) 2020-08-11
WO2018102294A1 (en) 2018-06-07
CO2019005247A2 (es) 2019-05-31
JP2019535716A (ja) 2019-12-12
MY200701A (en) 2024-01-11
AU2017366870B2 (en) 2024-09-19
MX2019006013A (es) 2019-10-14
MA46951A (fr) 2019-10-09
EP3548082A1 (en) 2019-10-09
IL266640A (en) 2019-07-31
EP3548082B1 (en) 2024-05-15
EA201991283A9 (ru) 2019-11-27
US20210060159A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
MY185813A (en) Factor xi antibodies and methods of use
WO2014144763A3 (en) High affinity anti-gd2 antibodies
WO2017097723A3 (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
WO2013071068A3 (en) Treatment of hematologic malignancies with an anti-cxcr4 antibody
AU2018290532A1 (en) Immunotherapy for hepatocellular carcinoma
GB201201314D0 (en) Composition
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
EP4434540A3 (en) Humanized anti-il-1r3 antibodies
IN2015DN02349A (enExample)
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
PH12019501087A1 (en) A pharmaceutical composition for averting opioid addiction
SG10201808867PA (en) Anti-nme antibody
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
NZ625758A (en) Method for treating breast cancer